Above Food Ingredients 주식 (NASDAQ: ABVE)

에 대한 최신 뉴스 Above Food Ingredients (NASDAQ:ABVE) 주식

Above Food Ingredients Inc is a differentiated, regenerative ingredient company. Its products are made with real nutritious, flavorful ingredients and delivered with transparency. Its vision is to create a healthier world one seed, one field, and one bite at a time. With a robust chain of custody of plant proteins, enabled by scaled operations and infrastructure in primary agriculture and processing, and proprietary seed development capabilities that leverage the power of artificial intelligence driven genomics. The company delivers nutritious foods to businesses and consumers with traceability and sustainability. Above Food's consumer products and brands are available in grocers across Canada and the United States.

Above Food Ingredients

Above Food Ingredients Inc. - Common Stock

Above Food Ingredients Inc

RBC Capital analyst Brad Erickson maintains GoDaddy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>) with a Outperform and lowers the price target from $230 to $225.

News

Price Target

Analyst Ratings

GDDY

RBC Capital Maintains Outperform on GoDaddy, Lowers Price Target to $225

RBC Capital analyst Tom Narayan maintains General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) with a Outperform and raises the price target from $55 to $57.

RBC Capital Maintains Outperform on General Motors, Raises Price Target to $57

As May opens for business, shell-shocked stock market investors are waving goodbye to April with both hands. While the major stock indexes have <a href="https://www.benzinga.com/markets/25/04/45027002/benzinga-bulls-and-bears-netflix-novavax-intel-and-the-market-begins-to-bounce-back">bounced back</a> moderately over the last week, stocks fell 11% at one point and declined 20% since mid-February, primarily due to <a href="https://www.benzinga.com/trading-ideas/25/04/45050322/how-youll-know-the-tariff-troubles-are-over">tariff troubles</a> affecting the global economy.
That's not all. Consumer spending was at a two-year low in the first quarter of 2025, while first-quarter US gross domestic product fell by 0.3%, fueling talk of a recession on the horizon.
Older traders are talking about a &#8220;Templeton Moment&#8221; right now, and likely with good reason. The term stems from legendary trader John Templeton, who famously borrowed $10,000 to buy shares in every company trading on the New York Stock Exchange for under $1 during a market trough in 1939, during the Great Depression. The list included 104 companies, including 34 that were bankrupt. A few years later, Templeton banked huge gains on all but four stocks when he sold.
Today&#8217;s market could be your opportunity for something similar.
"It doesn&#8217;t resemble a &#8216;Templeton Moment,&#8217; but I would be cautious," said Eugenia Mykuliak, founder and executive director at B2PRIME Group, a global financial services provider for institutional investors. "Today&#8217;s market has more nuances, and we're not close to an &#8216;extreme&#8217; pessimism, unlike the 1930s. Even though there are some well-valued stocks out there, that's certainly not an invitation to buy in bulk."
Unlike the 1930's, which saw economic indicators drag across the board, this market has largely fallen victim to one malady.
&#8220;Uncertainty has been generated by the announcement, delay, magnitude, and duration of tariffs," said Karl Farmer, portfolio manager at Rockland Trust Bank. "With over 40% of the S&amp;P 500's revenues coming from outside the US, the tariffs can have some big impacts on inventory management and purchase plans as producers and consumers face higher prices."
Resulting market uncertainty means less confidence in profit consistency and usually lower multiples that investors place on earnings.
"Higher costs likely lead to lower profits if sellers cannot pass on the price increases to their customers, or at a minimum, it leads to lower consumption," Farmer said. "A lower multiple coupled with lower profits means lower market levels. The longer the tariffs remain, the more likely there will be behavior changes by both producers and consumers, as many will seek alternatives if they believe that higher prices are not temporary."
If the delayed reciprocal tariffs are implemented in full and there have been few negotiated breakthroughs, "then we have not seen the bottom," Farmer added.
Here are today&#8217;s buying opportunities and what to look out for.
<h2 class="wp-block-heading">Stocks To Pounce On At Lower Market Levels</h2>
Templeton or no Templeton, when the markets slide significantly, there's always low-hanging fruit available, and the US stock market is no different. Here are a few names that stock market gurus like in a shallower pricing market.
British American Tobacco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTI#NYSE">BTI</a>). Sluggish stock markets spell opportunity for stocks that demonstrate good resilience amid uncertainty, especially those that turn to future-oriented technologies, Mykuliak said.
Shopify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NASDAQ">SHOP</a>). Mykuliak also likes stocks that offer investors a double dose of value.
"Shopify could be another good example of a perfect combination of AI and e-commerce, which are two powerful trends today," she said. "If merchants want to adapt to new retail realities, it&#8217;s a top choice for them."
Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>). According to Farmer, defensive sectors such as consumer staples and utilities have held up very well this year. "Presently, we favor some names in other areas that may have been overly punished, but could provide above-average returns for the patient investor," he said.
Nike tops that list. Nike is no quick fix for a 2025 portfolio, but it makes sense in this market.
"A pop could be had here if tariffs end quickly," Farmer said. "Nike did have issues even before tariffs, but it's a reinvigorating brand, and it's repairing relationships. Plus, Nike shares are down 70% from peak to 2017 levels, which provides a decent entry point."
Air Products and Chemicals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>). Air Products is a market leader in industrial gas trading at a big discount to competitor Linde (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>). "Future growth is coming from new projects and clean energy transition," Farmer said. "Additionally, the company has a strong and predictable recurring revenue model with on-site plants and 20-year contracts." Thermo Fisher Scientific (NYSE: TMO) is a market leader in life sciences, diagnostics and instruments.
"The stock is off 30% in the last three months on fears of spending cutbacks from customers who rely on federal funding for research," Farmer notes. "It's trading at less than market multiples for better earnings growth. Meanwhile, clarity on federal funding should mark a bottom."
<h2 class="wp-block-heading">More Than A "Buy the Dip" Scenario</h2>
As uncertainty prevails in the stock market, money managers are taking a more defensive stance with their portfolios, with one eye on historical trends.
"Historically, when volatility spikes—as it did in early April—the equity markets tend to see large gains one year later," said Andrew Constantinides, a financial advisor at Neil Jesani Wealth Management. "In the short term, however, calling the bottom is much harder. Investors should always remember: There can always be more downside in the market—unless it's at zero."
Constantinides said his firm is primarily focused on value and international stocks.
"Both categories have underperformed U.S. growth stocks over the past 10 years," he noted. "But Q1 of 2025 showed the first real signs of a cycle shift back toward value and international leadership. We favor developed markets, such as Europe and Asia. Our current sector focus is energy and financials—companies with low price-to-earnings ratios and high earnings yield. We have almost no exposure to large-cap tech."
<h2 class="wp-block-heading">5 Dark Horse Stocks Most Investors Aren't Following (But Should)</h2>
Every Friday, five overlooked stocks land on our ‘Whisper Index.' Like Coinbase before it surged 245% higher. And the biotech breakthrough Insmed before it jumped 20% in a single month. Beat Wall Street to these next potential winners. Access the Whisper Index <a href="https://www.benzinga.com/premium/ideas/benzinga-edge/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD0505&amp;utm_campaign=commandcenter">HERE</a>.
Editorial content from our Expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Opinion

Trading Ideas

SHOP

This Market Is The Buying Opportunity Of A Lifetime

RBC Capital analyst Deane Dray maintains Fortive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) with a Sector Perform and raises the price target from $68 to $72.

RBC Capital Maintains Sector Perform on Fortive, Raises Price Target to $72

RBC Capital analyst Rishi Jaluria maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Outperform and raises the price target from $30 to $35.

FIVN

RBC Capital Maintains Outperform on Five9, Raises Price Target to $35

RBC Capital analyst Ken Herbert maintains FTAI Aviation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) with a Outperform and lowers the price target from $140 to $130.

FTAI

RBC Capital Maintains Outperform on FTAI Aviation, Lowers Price Target to $130

WIIM

AZUL

RYAAY

VLRS

Shares of airline stocks are trading higher amid overall market strength following April's jobs data and reports that China's Commerce Ministry is assessing possible trade talks with the US. Better-than-feared jobs data and a potential trade deal could ease some concerns over consumer spending.

RBC Capital analyst Gerard Cassidy maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Sector Perform and raises the price target from $52 to $54.

EXAS

RBC Capital Maintains Sector Perform on Exact Sciences, Raises Price Target to $54

Eli Lilly and Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) on Thursday reported first-quarter earnings and <a href="https://www.benzinga.com/general/biotech/25/04/45112166/eli-lilly-stock-has-the-technicals-will-q1-earnings-deliver-fundamentals" target="_blank" rel="noreferrer noopener">lowered its 2025 guidance</a>.
The U.S. pharma giant reported January-March revenue of $12.73 billion, up 45% year over year and almost in line with the <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">consensus of $12.67 billion</a>. That was driven by a 53% increase in volume, partially offset by a 6% hit from lower realized prices and a 2% unfavorable impact of <a href="https://www.benzinga.com/general/biotech/25/05/45136276/mounjaro-maker-eli-lilly-clocks-45-jump-in-q1-revenue-cuts-2025-profit-outlook-but-not-due-to-tariffs" target="_blank" rel="noreferrer noopener">foreign exchange rates</a>.
Key Products revenue grew by&nbsp;$4.09 billion&nbsp;to&nbsp;$7.52 billion&nbsp;in Q1 2025, led by Mounjaro and Zepbound.
Eli Lilly reaffirmed its fiscal year 2025 <a href="https://www.benzinga.com/general/biotech/25/02/43525518/eli-lilly-q4-earnings-strong-demand-for-mounjaro-but-prices-dip-forecasts-over-30-jump-in-2025-sales-on-newer-medicines" target="_blank" rel="noreferrer noopener">sales guidance of $58 billion—$61 billion</a> versus a market consensus of $59.52 billion and $45.04 billion in 2024.
But it lowered the 2025 adjusted EPS outlook from $22.50-$24.00 to $20.78-$22.28, compared to the street consensus of $21.93, to reflect the impact of the Q1 2025 acquired IPR&amp;D.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/45051380/plaintiff-sues-eli-lilly-johnson-johnson-over-alleged-breast-cancer-risk-linked-to-antipsychotic-medications" rel="noreferrer noopener">Plaintiff Sues Eli Lilly, Johnson &amp; Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications</a>
Goldman Sachs analysts wrote in a note that Eli Lilly&#8217;s &#8220;decent set of 1Q25 results was overshadowed by <a href="https://www.benzinga.com/general/biotech/25/05/45147328/cvs-caremark-to-place-novo-nordisks-wegovy-on-preferred-coverage-for-glp-1-weight-loss-treatment" target="_blank" rel="noreferrer noopener">news of a formulary change announcement</a> by CVS Caremark that it is dropping the company&#8217;s Zepbound in favor of Novo Nordisk A/S&#8216; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy.&#8221;
&#8220;This has raised investor questions about pricing dynamics across the anti-obesity medication market. The combined price action in Eli Lilly and Nov Nordisk suggests investors are pondering smaller obesity TAM assumptions on pricing concerns. We believe these concerns are excessive,&#8221; Goldman analyst Asad Haider wrote.
Eli Lilly&#8217;s tirzepatide franchise strength, along with the robust orforglipron program for oral obesity, would have been rewarded had it not been for the CVS announcement, according to the Wall Street firm.
Haider maintains a buy rating on Eli Lilly and views the company as a leader in the anti-obesity market. According to the analyst, &#8220;sharp selloffs in LLY shares have presented a buying opportunity.&#8221;
Goldman Sachs lowered its Eli Lilly <a href="https://www.benzinga.com/quote/LLY/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $888 to $883</a> on Friday, reflecting PBM-related uncertainty.
BofA Securities on Friday noted Eli Lilly says it's reluctant to take part in &#8220;one-on-one&#8221; negotiations with insurers—where only one drug is chosen and companies are forced to compete head-to-head. The company believes it doesn't need to do that because Zepbound is a superior product.
&#8220;We think this whole CVS issue probably got more attention than it deserved&#8230;The CVS news does not mark a major, new negative trend, but does reflect the reality that no company ever has all payers locked up,&#8221; BofA Securities analyst Tim Anderson wrote.
BofA reiterates the Buy rating with a price target of $1,000.
Price Action: LLY stock is up 4.10% at $826.64 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45170433/kimberly-clark-commits-2b-to-us-expansion-overhaul" target="_blank" rel="noreferrer noopener">Kimberly-Clark Commits $2 Billion For US Expansion Overhaul</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Earnings

Large Cap

Guidance

Health Care

Movers

General

Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say

Billionaire Warren Buffett has a long history of his Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) conglomerate <a href="https://www.benzinga.com/general/education/25/01/42832123/warren-buffett-beats-sp-500-in-2024-how-oracle-of-omahas-returns-compare-over-past-20-years">outperforming the S&amp;P 500,</a> which is tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>).
While many stocks are down in 2025, one of Buffett's top holdings is significantly outperforming the broader market and could help him outperform in 2025 once again.
What Happened: Buffett's investment in Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), which remains his largest stock position in Berkshire Hathaway, has <a href="https://www.benzinga.com/general/education/24/08/40652464/warren-buffett-celebrates-94th-birthday-with-1-trillion-market-cap-milestone-a-look-back-at-hig">helped produce strong returns</a> but is turning into a sore spot in 2025.
Apple stock is down 15.9% year-to-date in 2025. In fact, of the five largest stock holdings in Berkshire Hathaway, only one is positive year-to-date as shown below:
<ul>
<li>Apple Inc: -15.9%</li>
<li>American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>): -7.1%</li>
<li>Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>): +15.3%</li>
<li>Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>): -7.3%</li>
<li>Chevron Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>): -5.3%</li>
</ul>
The Berkshire Hathaway portfolio includes positions in many stocks and one of the top performers year-to-date and over the last several years is Chinese automaker BYD Company ADR (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>).
The stock is up 49.1% year-to-date, up 69.3% over the last year and up 733.9% over the past five years. Along with beating Apple year-to-date, the five-year returns of the electric vehicle company also outpace Apple.
Buffett currently <a href="https://www.cnbc.com/berkshire-hathaway-portfolio/">owns </a>over 54 million shares of BYD valued at $2.7 billion. The stock represents around 1% of the Berkshire Hathaway portfolio with the conglomerate owning over 4% of the automaker.
While Buffett has <a href="https://www.benzinga.com/markets/equities/24/06/39481191/warren-buffets-berkshire-drops-byd-stake-despite-ev-leader-seeing-record-sales">trimmed the position</a> in BYD in recent years, he remains a key shareholder and the stock's gains are helping Berkshire Hathaway and the wealth of Buffett.
Berkshire Hathaway stock is up 19.3% year-to-date, outpacing the -3.0% performance of the SPY. Berkshire Hathaway has also outperformed the SPY on a one-year and five-year basis.
Buffett is now the sixth richest person in the world with a wealth of $166 billion, according to <a href="https://www.bloomberg.com/billionaires/?sref=TBDibEcD">Bloomberg</a>. Buffett has gained $23.6 billion in wealth and is the top gainer year-to-date among the world's billionaires.
Only three of the top 10 richest people in the world have added to their wealth in 2025, with six of the top 10 each losing $20 billion or more to their wealth totals.
Read Also: <a href="https://www.benzinga.com/25/04/44928468/warren-buffett-believer-in-american-companies-critical-of-tariffs-the-tooth-fairy-doesnt-pay-em">Warren Buffett, Believer In American Companies, Is Critical Of Tariffs: &#8216;The Tooth Fairy Doesn&#8217;t Pay &#8216;Em&#8217;</a>
Why It's Important: Buffett can thank companies like BYD that have gained in the Berkshire Hathaway stock portfolio for his increased wealth in 2025.
The growth may not be done for BYD as the company continues to expand in Europe and parts of Asia and is among the world's leaders in electric vehicle sales.
In March, BYD <a href="https://cnevpost.com/2025/04/10/automakers-share-of-china-nev-market-mar-2025/">was </a>number one in new electric vehicles sales in China, with 29.3% market share, outpacing Geely (11.2%) and Tesla (7.5%). In the first quarter of 2025, BYD had 28.8% market share for new electric vehicle sales in China.
A<a href="https://www.benzinga.com/25/04/45097773/satellite-images-put-tesla-rival-byds-hungarian-factory-capable-of-producing-200k-units-annually-in-the-spotlight"> new production facility</a> in Hungary is expected to produce 200,000 units a year and help BYD's expansion in Europe. The company is also considering another factory in the region, according to reports.
BYD sold 37,000 units in Europe in the first quarter of 2025, up from 8,500 units in the previous year.
In Japan and Australia, BYD is launching <a href="https://www.benzinga.com/news/management/25/01/42901570/warren-buffett-backed-byd-launches-australias-first-ev-under-30k-how-the-move-could-strengthen-fight-against-elon-musks-tesla">more affordable models</a> that could help expand its market share.
Future growth for BYD and continued stock gains could be important to Berkshire Hathaway continuing to outperform the S&amp;P 500 and for Buffett to grow his wealth.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/24/12/42734838/warren-buffetts-chilling-warning-to-employees-lose-a-shred-of-reputation-for-the-firm-and-i-will-be-ruthless">Warren Buffett&#8217;s Chilling Warning To Employees: &#8216;Lose A Shred Of Reputation For The Firm And I Will Be Ruthless&#8217;</a></li>
</ul>
Photo: Photo Agency via Shutterstock

Management

Global

AAPL

BYDDY

Warren Buffett Is Getting Richer In 2025 — And It's Not Because Of Apple: How One Chinese Holding Is Helping

ACGL

ALLY

ARES

ERIE

FINV

FUTU

HOOD

IBKR

KNSL

LMND

LPLA

MOGO

MORN

NTRS

PLMR

QFIN

SPNT

STEC

STEP

TROW

UPST

Shares of companies within the broader financial sector are trading higher amid overall market strength following April's jobs data and reports that China's Commerce Ministry is assessing possible trade talks with the US.

RBC Capital analyst Karl Shepard maintains Cullen/Frost Bankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFR#NYSE">CFR</a>) with a Sector Perform and lowers the price target from $147 to $140.

RBC Capital Maintains Sector Perform on Cullen/Frost Bankers, Lowers Price Target to $140

Melco Resorts & Entertainment Limited - American Depositary Shares

MLCO

Shares of travel-linked stocks are trading higher amid overall market strength following April's jobs data and reports that China's Commerce Ministry is assessing possible trade talks with the US. Better-than-feared jobs data and a potential trade deal could ease some concerns over consumer spending.

RBC Capital analyst Jonathan Atkin maintains Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) with a Sector Perform and raises the price target from $107 to $112.

RBC Capital Maintains Sector Perform on Crown Castle, Raises Price Target to $112

RBC Capital analyst Nik Modi maintains Church &amp; Dwight Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHD#NYSE">CHD</a>) with a Sector Perform and lowers the price target from $105 to $100.

RBC Capital Maintains Sector Perform on Church & Dwight Co, Lowers Price Target to $100

BOOT

BURL

DECK

LULU

Shares of retail and apparel stocks are trading higher on reports that China's Commerce Ministry is assessing possible trade talks with the US. Potential trade talks could ease some supply chain and consumer uncertainty in the sector.

<a href="https://www.benzinga.com/insights/analyst-ratings/25/05/45134453/the-analyst-verdict-robinhood-markets-in-the-eyes-of-21-experts#:~:text=Analysts%20provide%20deeper%20insights%20through,average%20price%20target%20of%20%2460.30.">Mizuho Securities analysts</a> remain optimistic about Robinhood&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) crypto business, despite trading volumes falling from a $15 billion monthly average in Q1 to $8 billion in April.
What Happened: Despite April&#8217;s volume decline, Mizuho Securities identified three key reasons to &#8220;stay constructive&#8221; on Robinhood&#8217;s crypto prospects:
<ul>
<li>April&#8217;s $8 billion in crypto volume, while lower than recent months, still exceeds historical averages. </li>
<li>Take rates are trending upward, with Q1 gross take rates reaching 57 basis points compared to 53 basis points in Q4 and just 37 basis points in the first half of 2024. </li>
<li>History suggests volumes per funded account rarely remain suppressed when Bitcoin prices rise, as they did by 10% in April.</li>
</ul>
&#8220;Take rates are moving up &#8211; and we believe they will continue that trajectory,&#8221; Mizuho analysts led by Dan Dolev wrote in a note <a href="https://www.theblock.co/post/352972/robinhood-crypto-volumes-dip-in-april-but-mizuho-sees-no-cause-for-concern?utm_source=rss&amp;utm_medium=rss">reported by</a> The Block on Friday. 
Dolev highlighted that Coinbase&#8217;s retail take rate is nearly three times higher, suggesting &#8220;ample upside potential&#8221; for Robinhood to continue raising its rates.
The firm maintained its &#8220;outperform&#8221; rating on HOOD shares while adjusting its price target from $80 to $65 and lowering second-quarter crypto volume estimates from $35 billion to $32 billion.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45170765/trumps-first-100-days-fuel-gold-crush-stocks-bofa-strategist-sees-soft-macro-masked-by-hard-ai-bets">Forget The Stock Market&#8217;s Tariff Turmoil. Trump&#8217;s Next 100 Days Could Bring A Bullish Trifecta That Reignites Demand, Expert Says</a>
What Experts Are Saying: Other analysts also <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45155666/robinhood-stock-falls-after-analysts-cite-weak-crypto-volumes-and-market-headwinds-in-q2-outlook">adjusted their outlooks</a> following the earnings report. 
JP Morgan&#8216;s Kenneth Worthington maintained a Neutral rating while raising his price target from $44 to $47.
He noted that despite softer crypto volumes, Robinhood still attracted a record $18 billion in net new deposits this quarter, with only about 15% due to promotions.
Piper Sandler&#8216;s Patrick Moley maintained an Overweight rating with a $70 price target, highlighting strong adoption of Robinhood&#8217;s newer offerings. 
During the earnings call, management revealed that futures, index options and prediction market products were each already generating approximately $20 million in annual run-rate revenue.
Robinhood CEO Vlad Tenev expressed enthusiasm about the prediction market performance, noting that over 1 billion contracts had been traded in the last six months across various events including U.S. elections and sports competitions. 
The company plans to &#8220;expand the offering into a wider variety of contracts over time,&#8221; according to Tenev.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45172683/wall-street-eyes-9th-straight-day-of-gains-apple-falls-as-chinese-sales-disappoint-whats-driving-markets-friday">Wall Street Eyes 9th Straight Day Of Gains, Apple Falls As Chinese Sales Disappoint: What&#8217;s Driving Markets Friday?</a></li>
</ul>
Photo Courtesy: Sergei Elagin On Shutterstock.com

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Robinhood's April Crypto Volumes Fall 47% From Q1 Average, But Analysts See 3 Reasons To 'Stay Constructive'

FCNCA

HBAN

Shares of banking companies are trading higher amid overall market strength following April's jobs data and reports that China's Commerce Ministry is assessing possible trade talks with the US.

RBC Capital analyst Deane Dray maintains Carrier Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) with a Outperform and raises the price target from $71 to $82.

CARR

RBC Capital Maintains Outperform on Carrier Global, Raises Price Target to $82

ACMR

AMAT

AOSL

ASML

AVGO

ENTG

FORM

HIMX

KLAC

LRCX

LSCC

MCHP

MKSI

NXPI

QCOM

RMBS

SMTC

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Shares of chip stocks are trading higher amid overall market strength on reports indicating China is assessing US trade talks. Additionally, jobs data may be easing some market fears. NVIDIA shares rose on reports indicating the company is working on China-tailored chips.

Press Releases

Above Food to Participate in the 44th Annual Canaccord Genuity Growth Conference

Above Food's Recent Montana-Based Asset Acquisition Expands Access to High-Growth Pet Food Market and Strengthens Chickpea Market Presence

Restaurants

Above Food Ingredients' subsidiary, Discovery Seed Labs, in Collaboration with BASF Canada, Develops Solution for Testing Disease Resistance in Lentils

Above Food Strengthens its Pet Food Ingredient Platform with Recent Montana-Based Asset Acquisition

Above Food Group Announces Strategic Restructuring to Accelerate Focus on Agri-Tech and Fin-Tech Sectors

Private Placement to Accelerate Growth and Enhance Profitability

Reporting Requirements

Above Food Ingredients Inc. Files Interim Financial Statements

Above Food Ingredients Inc. Files Financial Results for the Six-Month Period Ended July 31, 2024

Above Food Ingredients Inc. and Palm Global Technologies Advance Strategic Merger with Definitive Agreements Expected to be Signed Imminently

ABVE

ABVEW

Comments

Above Food Ingredients

뉴스

에 대한 최신 뉴스 Above Food Ingredients (NASDAQ:ABVE) 주식

뉴스

파트너 / 기고자

벤징가 글로벌